Considerations for Individualizing CDK 4/6 Inhibitor Therapy in Breast Cancer: Examining the Data and Agent-Specific Attributes

秒速飞艇正规平台

Pharmacy Technician

PTCB Recertification and State Required CE

START NOW

Pharmacist

Pharmacists Library

All the CE you need for 1 year to meet state requirements just $97.00.

START NOW
oatph

Considerations for Individualizing CDK 4/6 Inhibitor Therapy in Breast Cancer: Examining the Data and Agent-Specific Attributes (Recorded Podcast)

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Novartis Pharmaceuticals Corporation.

FACULTY

Rodney J. Hunter, PharmD, BCOP
Clinical Assistant Professor, Pharmacy Practice
Texas Southern University College of Pharmacy and Health Sciences
Clinical Pharmacy Specialist, Breast Oncology
University of Texas Health Memorial Hermann Cancer Center
Houston, TX

Amy L. Indorf, PharmD, BCOP
Clinical Oncology Pharmacist
UW Medicine
Seattle Cancer Alliance
Seattle, WA

FINANCIAL DISCLOSURE

Dr. Hunter has disclosed that he has served as a consultant for Novartis Oncology and on the speaker’s bureau for Lilly Oncology and Pfizer Oncology.

Dr. Indorf has disclosed that she has received financial support from the APP Oncology Summit.

The clinical reviewer, Megan May, PharmD, BCOP, has no actual or potential conflict of interest in relation to this program.

Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN-BC, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

ACCREDITATION STATEMENTS

PHARMACY
acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-20-096-H01-P
Credits: 0.75 hour (0.075 ceu)

Type of Activity: Knowledge
Media: Internet

Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 45 minutes (Recorded Podcast)

Published:

秒速飞艇正规平台 August 31, 2020

Expires:

秒速飞艇正规平台 August 31, 2021

TARGET AUDIENCE

秒速飞艇正规平台This accredited activity has been designed for oncology, managed care, and specialty pharmacists.

How to Earn Credit

During the period August 31, 2020 to August 31, 2021 participants must 1) read the learning objectives and faculty disclosures; 2) listen/view the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity。 To answer the questions, click on your selected choice for each answer then proceed to the next question。 Once completed, click on the Grade Exam button at the bottom of the page。 Your posttest will automatically be graded。 If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately。 Click on the View Statement of Participation link and print the statement for your records。 If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest。 You will have 2 opportunities to pass the posttest。 To receive Credit, you must provide your date of birth and NABP number。 All Credit information will be uploaded into CPE monitor within 30 days。

Goal

To improve the knowledge and competence of oncology, managed care, and specialty pharmacists on the pharmacology, efficacy, and safety of available CDK 4/6 inhibitors in patients with HR+/HER2– advanced breast cancer to ensure appropriate access to and use of these agents to individualize treatment and optimize outcomes.

LEARNING OBJECTIVES:

Upon completion of this program, participants should be better able to:

  • Discuss the mechanism of action, indications, and guideline recommendations for CDK 4/6 inhibitors in patients with HR+/HER2– advanced or metastatic breast cancer
  • Evaluate agent-specific efficacy and toxicity profiles of CDK 4/6 inhibitors to effectively individualize patient care

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Novartis Pharmaceuticals Corporation。 Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development。 The information presented in this activity is not meant to serve as a guideline for patient management。 Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities。

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this activity have not been evaluated by the FDA.

Postgraduate Healthcare Education, LLC (PHE) is the source of Power-Pak C.E.® continuing education for health care professionals. Our accredited programs assist in meeting the requirements of licensure. PHE provides continuing education for the broad spectrum of health care professionals. This site features a searchable database of accredited Power-Pak C.E.® courses on important topics for today's health care professionals.

PHE customizes Power-Pak C.E.® online for each visitor by creating a personal participant profile. Registered participants may update their contact information, take an exam, receive instant grading, view their exam history, and print certificates for successfully completed programs at any time. Monthly notifications will be sent to participants notifying you of new courses available on the site.

湖南快乐十分开奖 235棋牌 秒速飞艇官网 湖南快乐十分开奖 kk彩票开户 福建快3平台 秒速飞艇正规平台 山东十一运夺金开奖结果 掌上彩票注册 秒速飞艇官网